On April 19, 2024, at the Inaugural XDC New Drug Conference's grand gala event "Sky of Bio-Conjugates," Glotope was honored with the title of "Pioneer Enterprise in Nuclear Medicine Infrastructure." This recognition acknowledges Glotope's outstanding contributions to the field of nuclear medicine research and production.

During the two-day conference, Guotong New Drug engaged with industry leaders, highlighting high-potential targets in nuclear medicine R&D, sharing updates on radiopharmaceutical regulations, and discussing strategies for the full lifecycle development of radiopharmaceuticals.

Committed to addressing common challenges in the nuclear medicine industry, Glotope provides professional solutions to accelerate high-potential projects. The company remains dedicated to its customer-centric approach, offering services that enhance the nuclear medicine supply chain and bring better radiopharmaceutical diagnostics and therapeutics to patients worldwide.